A P Douglas1,2,3, K A Thursky4,5,6,7,8, L J Worth4,5,6,8, E Drummond9, A Hogg9, R J Hicks5,9, M A Slavin4,5,6,7. 1. Department of Infectious Diseases, Peter MacCallum Cancer Centre, 305 Grattan St, Parkville, Melbourne, VIC, Australia. abby.douglas@petermac.org. 2. University of Melbourne, Melbourne, Australia. abby.douglas@petermac.org. 3. The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia. abby.douglas@petermac.org. 4. Department of Infectious Diseases, Peter MacCallum Cancer Centre, 305 Grattan St, Parkville, Melbourne, VIC, Australia. 5. University of Melbourne, Melbourne, Australia. 6. The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia. 7. Victorian Infectious Diseases Service, The Peter Doherty Institute for Immunity and Infection, Royal Melbourne Hospital, Melbourne, Australia. 8. The National Centre for Antimicrobial Stewardship, Melbourne, Australia. 9. Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
Abstract
PURPOSE: Invasive fungal infections (IFIs) are common in immunocompromised patients. While early diagnosis can reduce otherwise high morbidity and mortality, conventional CT has suboptimal sensitivity and specificity. Small studies have suggested that the use of FDG PET/CT may improve the ability to detect IFI. The objective of this study was to describe the proven and probable IFIs detected on FDG PET/CT at our centre and compare the performance with that of CT for localization of infection, dissemination and response to therapy. METHODS: FDG PET/CT reports for adults investigated at Peter MacCallum Cancer Centre were searched using keywords suggestive of fungal infection. Chart review was performed to describe the risk factors, type and location of IFIs, indication for FDG PET/CT, and comparison with CT for the detection of infection, and its dissemination and response to treatment. RESULTS: Between 2007 and 2017, 45 patients had 48 proven/probable IFIs diagnosed prior to or following FDG PET/CT. Overall 96% had a known malignancy with 78% being haematological. FDG PET/CT located clinically occult infection or dissemination to another organ in 40% and 38% of IFI patients, respectively. Of 40 patients who had both FDG PET/CT and CT, sites of IFI dissemination were detected in 35% and 5%, respectively (p < 0.001). Of 18 patents who had both FDG PET/CT and CT follow-up imaging, there were discordant findings between the two imaging modalities in 11 (61%), in whom normalization of FDG avidity of a lesion suggested resolution of active infection despite a residual lesion on CT. CONCLUSION: FDG PET/CT was able to localize clinically occult infection and dissemination and was particularly helpful in demonstrating response to antifungal therapy.
PURPOSE:Invasive fungal infections (IFIs) are common in immunocompromised patients. While early diagnosis can reduce otherwise high morbidity and mortality, conventional CT has suboptimal sensitivity and specificity. Small studies have suggested that the use of FDG PET/CT may improve the ability to detect IFI. The objective of this study was to describe the proven and probable IFIs detected on FDG PET/CT at our centre and compare the performance with that of CT for localization of infection, dissemination and response to therapy. METHODS: FDG PET/CT reports for adults investigated at Peter MacCallum Cancer Centre were searched using keywords suggestive of fungal infection. Chart review was performed to describe the risk factors, type and location of IFIs, indication for FDG PET/CT, and comparison with CT for the detection of infection, and its dissemination and response to treatment. RESULTS: Between 2007 and 2017, 45 patients had 48 proven/probable IFIs diagnosed prior to or following FDG PET/CT. Overall 96% had a known malignancy with 78% being haematological. FDG PET/CT located clinically occult infection or dissemination to another organ in 40% and 38% of IFI patients, respectively. Of 40 patients who had both FDG PET/CT and CT, sites of IFI dissemination were detected in 35% and 5%, respectively (p < 0.001). Of 18 patents who had both FDG PET/CT and CT follow-up imaging, there were discordant findings between the two imaging modalities in 11 (61%), in whom normalization of FDG avidity of a lesion suggested resolution of active infection despite a residual lesion on CT. CONCLUSION: FDG PET/CT was able to localize clinically occult infection and dissemination and was particularly helpful in demonstrating response to antifungal therapy.
Authors: M Nucci; K A Marr; M J G T Vehreschild; C A de Souza; E Velasco; P Cappellano; F Carlesse; F Queiroz-Telles; D C Sheppard; A Kindo; S Cesaro; N Hamerschlak; C Solza; W J Heinz; M Schaller; A Atalla; S Arikan-Akdagli; H Bertz; C Galvão Castro; R Herbrecht; M Hoenigl; G Härter; N E U Hermansen; A Josting; L Pagano; M J C Salles; S B Mossad; D Ogunc; A C Pasqualotto; V Araujo; P F Troke; O Lortholary; O A Cornely; E Anaissie Journal: Clin Microbiol Infect Date: 2013-11-18 Impact factor: 8.067
Authors: Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079
Authors: Benjamin W Teh; Jasmine C Teng; Karin Urbancic; Andrew Grigg; Simon J Harrison; Leon J Worth; Monica A Slavin; Karin A Thursky Journal: Haematologica Date: 2014-10-10 Impact factor: 9.941
Authors: George Crișan; Nastasia Sanda Moldovean-Cioroianu; Diana-Gabriela Timaru; Gabriel Andrieș; Călin Căinap; Vasile Chiș Journal: Int J Mol Sci Date: 2022-04-30 Impact factor: 6.208
Authors: Melissa D Johnson; Russell E Lewis; Elizabeth S Dodds Ashley; Luis Ostrosky-Zeichner; Theoklis Zaoutis; George R Thompson; David R Andes; Thomas J Walsh; Peter G Pappas; Oliver A Cornely; John R Perfect; Dimitrios P Kontoyiannis Journal: J Infect Dis Date: 2020-08-05 Impact factor: 5.226
Authors: Hassan O J Morad; Anna-Maria Wild; Stefan Wiehr; Genna Davies; Andreas Maurer; Bernd J Pichler; Christopher R Thornton Journal: Front Microbiol Date: 2018-08-23 Impact factor: 5.640
Authors: Alfred O Ankrah; Dina Creemers-Schild; Bart de Keizer; Hans C Klein; Rudi A J O Dierckx; Thomas C Kwee; Lambert F R Span; Pim A de Jong; Mike M Sathekge; Andor W J M Glaudemans Journal: Diagnostics (Basel) Date: 2021-01-17
Authors: Alfred O Ankrah; Lambert F R Span; Hans C Klein; Pim A de Jong; Rudi A J O Dierckx; Thomas C Kwee; Mike M Sathekge; Andor W J M Glaudemans Journal: Eur J Nucl Med Mol Imaging Date: 2018-10-21 Impact factor: 9.236
Authors: Monica A Slavin; Yee-Chun Chen; Catherine Cordonnier; Oliver A Cornely; Manuel Cuenca-Estrella; J Peter Donnelly; Andreas H Groll; Olivier Lortholary; Francisco M Marty; Marcio Nucci; John H Rex; Bart J A Rijnders; George R Thompson; Paul E Verweij; P Lewis White; Ruth Hargreaves; Emma Harvey; Johan A Maertens Journal: J Antimicrob Chemother Date: 2021-12-24 Impact factor: 5.790